WESTFORD, Mass., Nov. 10, 2016 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced that President and Chief Executive Officer Michael Davin and Steve Webber, the Company's Chief Financial Officer and Chief Accounting Officer, will participate in the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York City.
The event, which will be conducted in a "fireside chat" format, is scheduled for 8:00 a.m. (ET) Wednesday, November 16. Both live and archived audio webcasts of the event will be accessible through a link on the Investors section of the Company's website, www.cynosure.com.
About Cynosure, Inc. Cynosure develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF) energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and RF technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.
Contact: Scott SolomonSenior Vice PresidentSharon Merrill Associates, [email protected]
Advertisement
The event, which will be conducted in a "fireside chat" format, is scheduled for 8:00 a.m. (ET) Wednesday, November 16. Both live and archived audio webcasts of the event will be accessible through a link on the Investors section of the Company's website, www.cynosure.com.
Advertisement
About Cynosure, Inc. Cynosure develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF) energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and RF technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.
Contact: Scott SolomonSenior Vice PresidentSharon Merrill Associates, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cynosure-to-participate-in-stifel-2016-healthcare-conference-300360575.html
SOURCE Cynosure, Inc.
